Reply to: HEP-21-0945.R1

We appreciate the interest of Jindal et al. in our article recently published in Hepatology on response to terlipressin and albumin and post-transplant outcomes in patients with hepatorenal syndrome (AKI-HRS). They raised four important points. The first one allow us to strengthen further the message that a liver transplant (LT) allocation policy based on weekly updates of MELD/MELD-Na score may have a negative impact on responders to treatment with terlipressin and albumin. This is the reason why baseline MELD/MELD-Na score (pre-treatment value) is currently used for LT prioritization in responders to terlipressin and albumin in some regions.